[A25-84] Sipavibart (pre exposure prophylaxis of COVID 19) – Addendum to Project A25-28
Last updated 07.08.2025
Project no.:
A25-84
Commission:
Commission awarded on 24.06.2025 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Immune system and infections
Pre-exposure prophylaxis of COVID-19 in adults and adolescents 12 years of age and older weighing at least 40 kg and who are immunocompromised due to a medical condition or receipt of immunosuppressive treatments
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
https://doi.org/10.60584/A25-84
| Project no. | Title | Status |
|---|---|---|
| A25-28 | Sipavibart (pre-exposure prophylaxis of COVID-19) – Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
07-08-2025 A G-BA decision was published.
G-BA documents on this decision